Global BioAccess Fund

At the Global BioAccess Fund we partner with forward-thinking companies to create the medicines of tomorrow. We invest in transformative technologies that address unmet needs in Oncology, I&I, cardiovascular, CNS, and rare diseases. We fund early-stage companies who need capital to support IND submission and clinical trials. We most often invest from Series A to Series C. However, we can participate as late as crossover financings. We can invest up to $10M throughout the lifespan of a company. However, with our limited partners (LPs) we can invest additional funds in later stage rounds.